Quick Answer
Elanco Animal Health Inc reported Research And Development Expense of $368.00 million for the year ending 2025.
- Elanco Animal Health Inc showed an increase of +7.0% in Research And Development Expense from 2024 to 2025.
- This data is from Elanco Animal Health Inc's annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $61.90 million | Q1 2018: $65.20 million | Q2 2018: $61.40 million | Q3 2018: $58.90 million | Q1 2019: $64.10 million | Q2 2019: $68.80 million | Q3 2019: $69.90 million | Q1 2020: $67.00 million | Q2 2020: $59.00 million | Q3 2020: $88.00 million | Q1 2021: $89.00 million | Q2 2021: $94.00 million | Q3 2021: $94.00 million | Q1 2022: $81.00 million | Q2 2022: $82.00 million | Q3 2022: $78.00 million | Q1 2023: $81.00 million | Q2 2023: $81.00 million | Q3 2023: $86.00 million | Q1 2024: $87.00 million | Q2 2024: $89.00 million | Q3 2024: $87.00 million | Q1 2025: $94.00 million | Q2 2025: $92.00 million | Q3 2025: $89.00 million.
- Over the full 10 years of available data (2016 to 2025), Elanco Animal Health Inc's Research And Development Expense has grown by 38.4%.
- Historical annual values: Fiscal year 2025: $368.00 million | Fiscal year 2024: $344.00 million | Fiscal year 2023: $327.00 million | Fiscal year 2022: $321.00 million | Fiscal year 2021: $369.00 million | Fiscal year 2020: $329.00 million | Fiscal year 2019: $270.00 million | Fiscal year 2018: $246.60 million | Fiscal year 2017: $251.70 million | Fiscal year 2016: $265.80 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: